Fig. 7From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trialPre-infusion plasma lysosphingomyelin levels during placebo or olipudase alfa treatment periods. The dashed line indicates the upper limit of normal. (Note: The increase in mean level at week 104 resulted from multiple missed infusions by two participants.)Back to article page